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Abstract
Background: Although not recommended in treatment guidelines, previous studies have shown a frequent use of
more than one antipsychotic agent among patients with schizophrenia. The main aims of the present study were
to explore the antipsychotic treatment regimen among patients with schizophrenia in a catchment area-based
sample and to investigate clinical characteristics associated with antipsychotic combination treatment.
Methods: The study included 329 patients diagnosed with schizophrenia using antipsychotic medication. Patients
were recruited from all psychiatric hospitals in Oslo. Diagnoses were obtained by use of the Structured Clinical
Interview for DSM-IV Axis I disorders (SCID-I). Additionally, Global Assessment of Functioning (GAF), Positive and
Negative Syndrome Scale (PANSS) and number of hospitalisations and pharmacological treatment were assessed.
Results: Multiple hospital admissions, low GAF scores and high PANSS scores, were significantly associated with
the prescription of combination treatment with two or more antipsychotics. The use of combination treatment
increased significantly from the second hospital admission. Combination therapy was not significantly associated
with age or gender. Regression models confirmed that an increasing number of hospital admission was the
strongest predictor of the use of two or more antipsychotics.
Conclusions: Previous hospital admissions and disease severity measured by high PANSS scores and low GAF
scores, predict the use of antipsychotic combination treatment in patients with schizophrenia. Future studies
should further explore the use of antipsychotic drug treatment in clinical practice and partly based on such data
establish more robust treatment guidelines for patients with persistently high symptom load.
Background
Evidence-based recommendations and guidelines for
psychopharmacological treatment of schizophrenia are
regarded as important tools to improve the quality of
clinical treatment, to guide decision-making and to
reduce inappropriate variations in clinical practice [1].
The guidelines also intended to offer a more rational
treatment strategy and thereby optimizing the therapeu-
tic efficacy and reduce the side effects [2-4]. Even so,
prescriptions of antipsychotics have often deviated from
expert recommendations [1,5], and treatment guidelines
are not implemented for all schizophrenia patients [6,7].
Since up to 90% of patients with schizophrenia may be
excluded from clinical trials, there will naturally be a
gap between clinical practice and study reports on the
efficacy of treatment [8]. The variation in prescription
patterns across different regions and countries [1,9,10]
could also be due to differences in therapeutic traditions
and treatment settings, attitudes towards antipsychotic
drugs or cultural factors among psychiatrists.
It has been proposed that antipsychotic combination
regimens are more frequently prescribed when the clini-
cal course of the illness is complex or in treatment-
resistant patients [10,11]. Studies of hospitalized patients
with schizophrenia indicate a higher rate of antipsycho-
tic combination treatment and use of First Generation
Antipsychotics (FGA) compared to guideline recommen-
dations [10,12,13]. Differences in prescription patterns
could therefore be related to disease characteristics [1],
although this has not yet been investigated in any
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catchment area sample representative of the majority of
patients with schizophrenia.
The aim of this study was to explore the prescription
pattern of antipsychotics among a sample of patients
with schizophrenia receiving pharmacological treatment.
The following research questions were addressed: 1)
What types of antipsychotic medications are used in the
treatment of schizophrenia in a Norwegian naturalistic
catchment area sample? 2) Is the use of two or more
antipsychotics associated with the severity of the disease
as measured with the Global Assessment of Function
(GAF), Positive and Negative Syndrome Scale (PANSS)
and/or number of hospitalisations?
Methods
Sample
All the psychiatric hospitals in Oslo participate in the
cross-sectional Thematically Organized Psychosis (TOP)
Study, in which patients with psychotic disorders were
recruited from outpatient as well as inpatient hospital
units in a catchment area-based psychiatric service from
2003 to 2010. Up to 2008, we do not possess accurate
data concerning out- or inpatient status at the time of
inclusion in the study. A number of patients were
recruited while being hospitalized, but actually included
after discharge. The TOP study includes patients with a
DSM-IV [14] diagnosis of schizophrenia and schizoaffec-
tive disorders, bipolar disorders and psychosis NOS.
Patients were excluded if there was a previous history of
head trauma, serious somatic illness or they were unable
to give written, informed consent. For further informa-
tion about the inclusion procedures, see [15-17]. A total
of 329 patients, 213 (64.7%) men and 116 (35.3%)
women, with schizophrenia fulfilled the inclusion cri-
teria of the present study, including current use of anti-
psychotic medication and information on previous
treatment history (For further patient characteristics, see
Table 1).
The protocol was approved by The Norwegian Data
Inspectorate and by the Regional Committee for Medi-
cal Research Ethics. All included patients received both
written and oral information about the study and gave
their written consent. The study was performed in full
accordance with the Declaration of Helsinki (1965) and
later revisions.
Assessment
All patients included in the study went through the
Structured Clinical Interview for DSM-IV Axis I disor-
ders (SCID-I) [18] for diagnostic purposes. All raters
were investigators in the study, with a background either
as medical doctor or clinical psychologist. The raters
were trained in clinical interviews and assessments
including video and case report ratings. Tests for rating
reliability were performed for the different diagnoses,
PANSS and GAF scores. The diagnostic reliability was
found to be satisfactory with an overall agreement for
DSM-IV diagnostic categories of 82% with  = 0.77
(95% CI: 0.60-0.94). The level of functioning was
assessed by use of the split version of the Global Assess-
ment of Functioning scale (GAF) [18]. The GAF rating
was carried out by the investigators, with a satisfactory
inter-rater reliability for GAF-F (ICC (1.1) = 0.86).
Relevant information on present and former drug
treatment and previous hospitalisation were obtained
from patient interviews and hospital records. If a patient
used more than one antipsychotic drug at the time of
the study, the drug prescribed in the highest dose, esti-
mated from Defined Daily Doses (DDD), was defined as
the primary therapeutic agent. If prescribed doses of
two or more antipsychotics were equipotent, the medi-
cation with the longest duration was defined as the
Table 1 Background variables of patients included in the study (n = 329#)
Mean (S.D) Median (min. - max.)
Age (years), (n = 329) 31.9 (9.6) 30 (17-60)
Age of psychosis onset (years) (n = 140) 23.8 (8.3) 22 (7-54)
Duration of untreated psychosis (weeks) (n = 142)) 134 (182) 76 (0-1040)
GAF-Symptom (n = 329) 40.0 (10.5) 38 (8-81)
GAF-Function (n = 329) 41.0 (9.5) 40 (21-81)
PANSS-positive (n = 305) 16.3 (5.9) 16 (7-32)
PANSS-negative (n = 307) 17.0 (6.6) 16 (7-43)
PANSS-general(n = 304) 33.3 (8.7) 33 (16-69)
PANSS-total (n = 302) 66.7(7.0) 67 (30-144)
Previous hospital admissions (n = 329) 3.5(5.3) 2 (0-40)
S.D.; standard deviation, GAF; Global Assessment of Functioning PANSS, Positive and Negative Syndrome Scale,
# A total of 329 patients, 213 (64.7%) men and 116 (35.3%) women, with schizophrenia were included. Among these 261 (79.3%) patients fulfilled the DSM-IV
(16) criteria for the paranoid type of schizophrenia, 40 (12.2%) patients undifferentiated type, 16 (4.9%) disorganized type, 11(3.3%) residual type and 1 (0.3%)
catatonic type.
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primary therapeutic agent. Secondary and tertiary thera-
peutic agents were established in line with this.
Statistical analysis
Descriptive statistics was used for the initial analyses of
frequencies, means and standard deviations (SD). Inde-
pendent sample t-tests were used on between-group
comparisons of means. Mann-Whitney test were used
when skewed distribution of data were assumed. When
dichotomous variables, we used Pearson Chi Square
tests. Significant relationships were further explored by
using a Backward Stepwise logistic regression model.
Due to the low accuracy on the present inpatient versus
outpatient treatment status, we did not include this fac-
tor in the logistic regression analyses. The effect sizes
are presented as odds ratios. Nagelkerke’s R-square was
used to indicate goodness of fit. All analyses were per-
formed using the Statistical Package for Social Sciences
(SPSS), Version 14.
Results
A total of 329 patients received antipsychotic pharmaco-
logical treatment as their primary therapeutic medica-
tion. Out of these, 305 (92.7%) patients received a
second-generation antipsychotic (SGA) and 24 (7.3%)
patients received a first generation antipsychotic (FGA).
Olanzapine was the most frequent used primary
medication (31.6%), followed by Quetiapine (17.6%), Ari-
piprazol (15.5%) and Risperidon (including Risperdal
Consta) (12.4%), (See Table 2).
A total of 101 (30.7%) patients used two or more anti-
psychotics in combination. FGAs were used somewhat
less frequent than SGAs (39 vs. 63 cases) as a second
antipsychotic. Only 12 (3.2%) of the patients used three
or more antipsychotics. The combination of SGA +
SGA was used in 61 patients, SGA+ FGA in 37 patients,
FGA+ FGA in only 2 patients and FGA + SGA were
not used by any patient in this sample.
Patients using two or more antipsychotics scored on
average significant lower on GAF-function and GAF-
symptoms, while they scored significantly (p < 0.05)
higher on PANSS-positive symptom scale and PANSS-
negative symptom scale. However, they did not score
significantly higher on the PANSS-general symptom
scale (p = 0.056) and there was no association with age
(See Table 3 and 4).
Number of previous admissions in the group of
patients using only one antipsychotic drug was signifi-
cantly lower than in the group of patients using two or
more antipsychotic drugs (Mann-Whitney U = 8482,50,
Z = -3.861, p-value = 0.000, r = -0.2129). Duration of
untreated psychosis (DUP) did not differ significantly
between the groups (Mann-Whitney U = 1790.00, Z =
-1.134, p value = 0.257, r = -0.0951).
Table 2 Received primary therapeutic agent (PTA) in the study population, n = 329
Drug or treatment regimen No. of patients (%) Mean daily dose mg* CPZ equivalents mg**
Second generation antipsychotic (SGA) 305 (92.7%)
Olanzapine 104 (31.6%) 14.4 288
Risperidon or Risperdal Consta 41 (20.6%) 3.7 244
Quetiapine 58 (17.6%) 537,5 698
Aripiprazole 51 (15.5%) 14.2 189
Ziprasidon 20 (6.1%) 85.8 137
Amisulpride 11 (3.3%) 615.9 616
Clozapine 16 (4.8%) 390.6 391
Sertindole 4 (1.2%) 18.2 342
First generation antipsychotic (FGA) 24 (7.3%)
Perphenazine or Perphenazine decan. 12 (3.6%) 8.9 111
Zuclopenthixol or Zuclopenthixol decan. 6 (2.1%) 20.0 80
Chlorprothixen 3 (0.9%) 116.7 233
Levomepromazine 1 (0,3%) 120 120
Chlorpromazine 1 (0.3%) 30.0 120
Flupentixol 1 (0.3%) 1.0 50
Haloperidol 0 (0%)
No. of patients using only one antipsychotic drug 228 (69.3%)
No. of patients using more than one antipsychotic drug 101 (30.7%)
*Per oral medication only.
** CPZ equivalents; Chlorpromazine equivalents according to Kroken et al 2009: http://www.biomedcentral.com/1471-244X/9/24/table/T1
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Pearson Chi-Square showed a significant relationship
between two or more previous admissions and antipsy-
chotic combination treatment (Value 9.086; Asymp. p-
value = 0.003).
However, Pearson Chi-Square did not show any signif-
icant relationship between gender and antipsychotic
combination treatment (Value 0.009; Asymp. p-value =
0.922). We have information on inpatient versus outpa-
tient status in only 161 out of 329 patients. Only 12
(16.7%) out of 72 outpatients received antipsychotic
combination treatment while 33 (37.1%) out of 89 inpa-
tients at the time of inclusion received antipsychotic
combination treatment. We found a significant relation-
ship between inpatient status and antipsychotic combi-
nation treatment (Pearson Chi-Square Value 9.045;
Asymp. p-value = 0.003).
As displayed in Table 5, the probability of two or
more antipsychotics being used increased with the num-
ber of previous admissions to a psychiatric hospital.
Among patients with two or more previous admissions,
36.8% received combination treatment. In contrast, only
21.9% of the patients with one or no previous admis-
sions, and only 18.4% of patients not previously
admitted, received such treatment. There was a nominal
increase in patients receiving two or more antipsychotics
up to the fourth previous admission. However, the por-
tion of patients receiving two or more antipsychotics did
not further increase with higher numbers of previous
admissions. We used a stepwise backward logistic
regression model exploring the individual strength of
the possible predictors. We entered GAF-symptom,
GAF-function, PANSS-positive, PANSS-negative,
Table 3 Group wise comparing of means
Patients with one antipsychotic Patients with two or more antipsychotics
Mean Mean
Age (n = 329) 32.12 31.32
Age at onset of psychosis (n = 140) 24.11 23.06
Duration (weeks) of untreated psychosis (n = 142) 151 91
GAF-S (n = 329) 41.51 36.65
GAF-F (n = 329) 42.32 38.15
PANSS-positive (n = 305) 15.81 17.38
PANSS negative (n = 307) 16.16 18.82
PANSS general (n = 304) 32.75 34.82
PANSS total (n = 302) 64.65 71.29
Number of previous admissions(n = 329) 2.916 4.881
GAF-S; Global Assessment of Functioning,-Symptom, GAF-F Global Assessment of Functioning, - Functions, PANSS; Positive and Negative Syndrome Scale
Table 4 Independent sample t-test comparing group of patients with one antipsychotic versus patients with two or
more antipsychotics
T-test for equality of means
t Sig (2-tailed) 95% Confidence for the difference
Lower - Upper
Age (n = 329) 0.689 0.486 -1.457 - 3.060
Age at onset of psychosis (n = 140) 0.795* 0.429 -1.583 - 3.692
Duration (weeks) of untreated psychosis (n = 142) 2.318* 0.022 8.757 - 110.567
GAF-S (n = 329) 3.971 0.000 2.452 - 7.267
GAF-F (n = 329) 3.734 0.000 1.972 - 3.363
PANSS-positive (n = 305) -2.187 0.030 -2.997 - -0.158
PANSS negative (n = 307) -3.297 0.001 -4.239 - -1.070
PANSS general (n = 304) -1.916 0.056 -4.195 - -0.056
PANSS total (n = 302) -3.133 0.002 -10.821 - -2.471
Number of previous admissions (n = 329) -2.859* 0.005 - 3.323 - -0.606
No. of previous admission dichotomized,
(0 or 1 vs. 2 or more previous admissions)
-3.189* 0.002 -0.284 - -0.067
* Equal variances not assumed due to Levene’s Test for Equality of Variances, p < 0.05
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PANSS-general sub score and previous admissions into
the regression model. The number of previous admis-
sions was dichotomized into two groups, less than two
admissions versus two or more admissions. Two or
more previous hospital admissions appeared to be the
far strongest predictor of combination treatment, fol-
lowed by a low GAF symptoms score and a high
PANSS-negative symptoms score (Table 6) The group
of patients with two or more previous admissions
showed an odds ratio of 2.445, for receiving two or
more antipsychotics compared to patients with no or
one previous admissions. Nagelkerkes R Square was
0.135 for the last step.
Discussion
The main finding of this study is that the prevalence of
antipsychotic combination treatment increased with
number of hospital admissions, severity of the disease as
measured with PANSS, and level of dysfunction, as mea-
sured with GAF. The current finding that previous hos-
pital admissions were related to antipsychotic
combination treatment is in line with Kroken el. al [9]
who found that in-patient treatment in the previous 12
months predicted polypharmacy. As seen from table 5,
increase in number of hospital admissions beyond four
did not seem to increase to probability of receiving two
or more antipsychotics. We dichotomized the sample
and chose a cut-off between one and two previous
admissions. The reason for choosing this cut-off value
was primarily the clinical relevant distinction between
patients who were readmitted and those who were not.
In a number of the patients first admittance to hospital
was not necessarily due to problems with ongoing
treatment, but due to a more acute or dramatic onset of
symptoms of schizophrenia. Choosing a cut-off between
one and two admissions therefore reflects to a greater
extend patients with poor compliance or lack of
response to ongoing treatment.
The cut-off points could just as well have been set
between two and three, or between three and four pre-
vious admissions, providing slightly higher odds ratios.
However, more than five previous admissions did not
further increase the probability of receiving an antipsy-
chotic combination treatment. Our results seem to be in
line with studies that suggest a combination of antipsy-
chotics as an option in non-responders with a higher
degree of relapse, or in patients with more severe schi-
zophrenia [5,12,19,20]. The finding that the use of anti-
psychotics were mainly in accordance with guidelines up
to the second admission to hospital, supports the
hypothesis that antipsychotic combination therapy is
more likely to be prescribed when treatment according
to guidelines has not achieved an adequate therapeutic
response.
Previous studies have not reported any significant cor-
relation between prescription pattern and decline in glo-
bal- or daily functioning, measured with GAF [9,21].
This could be due to a type II error, at least in one of
the studies, since this only included inpatients [9]. The
current finding of PANSS score versus combination
treatment, has not been reported earlier. A higher level
of current psychotic symptoms, as measured with total
PANSS scores, further supports the hypothesis that anti-
psychotic combination therapy is more likely to be pre-
scribed when guideline treatments have not achieved an
adequate therapeutic response.
Table 5 Number of previous hospital admissions; comparison of patients with only one antipsychotic versus patients
with two or more antipsychotics
No. of previous admissions to psychiatric ward
0 1 2 3 4 5 6 7 8+
N = 329 49 79 63 39 29 14 13 13 30
One antipsychotic 228
(69.3%)
40
(81.6%)
61
(77.2%)
46
(73.0%)
28
(71,8%)
13
(44.8%)
8
(57.1%)
8
(44.8%)
8
(61.5%)
16
(53.3%)
Two or more antipsychotics 91
(30.7%)
9
(18.4%)
18
(22.8%)
17
(27.0%)
11
(28.2.%)
16
(55.2%)
6
(42.9%)
5
(38.5%)
5
(38.5%)
14
(46.7%)
Table 6 Logistic regression model; Backward Stepwise (Wald) Previous admissions dichotomized 0-1 versus 2 or more
Patient factor Odds Ratio (Exp.(B)) 95.0% C.I. for OR P-value Wald
Lower - Upper
Step 4 (last step) *
GAF-Symptom 0.953 0.924 - 0.983 0.002 9.239
PANSS-negative symptoms 1,048 1.007 - 1.090 0.022 5.242
Two or more hospital admissions 2.445 1.416 - 4.225 0.001 10.258
GAF; Global Assessment of Functioning, PANSS; Positive and Negative Syndrome Scale, OR; Odds Ratio
*Nagelkerke R Square = 0.135
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Our naturalistic sample of patients consisting of both
inpatients and outpatients at the time of the examina-
tion, might be more representative for the population of
patients with schizophrenia at various stages of the ill-
ness, providing a relatively wide spectrum in symptom
levels and functioning and thus GAF and PANSS scores.
This probably enabled us to detect important associa-
tions that are difficult to find in more selected groups of
patients e.g. inpatients only.
Duration of untreated psychosis (DUP) was verified
in only a portion of the patients but did not show any
significant relationship to combination treatment with
antipsychotics. This may be in line with our finding
that age did not show any significant relationship with
such treatment either. Future studies should further
explore the role of DUP with regard to medication
regimens.
The overall rate of antipsychotic combination treat-
ment among our patients was comparable to other nat-
uralistic studies [9,12]. In our study SGAs were used
more frequently as the preferred antipsychotic drug
than reported from some European studies performed
during the same time period [9,11,22,23], but was in
line with other study reports [24]. The use of FGA as a
primary therapeutic agent was relatively infrequent in
our study. The variation in prescription patterns of
SGAs may be attributed to both guideline adherence
and how the public health systems work in different
countries, including to what extent prescriptions of all
antipsychotic medications are reimbursed by the social
security program, as well as differences in the hospitals’
financial schemes which influence the choice of low-ver-
sus high-cost medications.
Evidence-based guidelines for the psychopharmacolo-
gical treatment of schizophrenia are important for
securing a high quality of clinical practice including
rational strategies to minimize adverse effects. However,
the knowledge is rather scarce on how to guide treat-
ment decisions in non-responders to antipsychotic
monotherapy, which may be reflected by the lack of evi-
dence-based recommendations for this group of schizo-
phrenia patients. A better discrimination between
subgroups of patients with different clinical courses of
the illness is therefore needed when proposing new
recommendations, moving today’s guidelines with their
“one size fits all” approach to antipsychotic medications
closer to clinical practice.
The current body of evidence to support a combina-
tion of two or more antipsychotics in schizophrenia is
not conclusive [20,24-26], even though antipsychotic
combination treatment may be superior to monotherapy
in a limited number of patients [12,26,27]. A few rando-
mized controlled trials have reported treatment with
clozapine in combination with a second antipsychotic,
to be superior to clozapine in monotherapy in sub-
groups of patients [27].
The current study involved all psychiatric hospitals in
Oslo and included both in- and outpatients. The public
health care service in Norway is good and provides ade-
quate treatment for all psychiatric patients. There is no
privately financed health care that offers long-term
treatment for patients with schizophrenia, which
enabled us to collect representative data on current
treatment with a rather low degree of selection bias.
Limitations
Our data are based on a sample of cooperating patients
who agreed to join the study, including all assessments
and interviews. Many patients were outpatients, indicat-
ing a higher degree of treatment compliance compared
to inpatients or long-term hospitalized patients. In con-
trast, studies that only recruit inpatients may have a
selection bias towards more severe and treatment-refrac-
tory cases.
Conclusions
Patients with previous hospital admissions and disease
severity measured by high PANSS scores and low GAF
scores were more likely to receive an antipsychotic com-
bination treatment. Future studies should further
explore the use of antipsychotic drug treatment in clini-
cal practice and partly based on such data establish
more robust treatment guidelines for patients with per-
sistently high symptom load.
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